Sign in
Taking people in United StatesPhase 4

Compares 2-dose and 3-dose hepatitis B vaccine schedules in people with cirrhosis

Tests 2-dose versus 3-dose Heplisav B vaccine in adults with cirrhosis.

Key facts

Who runs it
Mercy Medical Center
Where
Baltimore, United StatesSee the site
Trial code
Registry title
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Status
Recruiting
Phase
Phase 4
People taking part
200 people, planned
Started
14 Sept 2020
Expected to end
1 Dec 2028
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Heplisav-B Injectable Product, 2-dose regimen
  • Heplisav-B Injectable Product, 3-dose regimen
Record updated
19 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cirrhosis who are not immune to hepatitis B. It compares a 2-dose and a 3-dose Heplisav B vaccine schedule.

Age
More than 18 years old
Sex
All sexes can join
Disease stage
Cirrhosis of the liver
Biomarker or test result
No immunity against hepatitis B: anti-HBs titer < 10 mIU/ml

Main reasons for not taking part

  • Serious allergic reaction to a prior dose of the hepatitis B vaccine, to a vaccine component, or to yeast
  • Previous exposure to hepatitis B
  • Liver transplant already done
  • Less than 18 years old

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer < 10 mIU/ml) will be recruited

Who cannot take part

  • Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine
  • Those who had previous exposure to hepatitis B
  • Post liver transplant patients
  • Less than 18 years old

Where in United States

  • Mercy Medical CenterBaltimore, United StatesContact: CHAU TO, MDTaking people

About the trial

What the trial wants to find out

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

The 4 groups in the trial

  • Cirrhosis, 3-dose regimenTreatment being tested

    Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.

    Treatment: Heplisav-B Injectable Product, 3-dose regimen

  • Cirrhosis, 2-dose regimenExisting treatment, for comparison

    Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.

    Treatment: Heplisav-B Injectable Product, 2-dose regimen

  • Non cirrhosis, 3-dose regimenTreatment being tested

    Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.

    Treatment: Heplisav-B Injectable Product, 3-dose regimen

  • Non cirrhosis, 2-dose regimenExisting treatment, for comparison

    Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.

    Treatment: Heplisav-B Injectable Product, 2-dose regimen

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.
Plain-language title
Compares 2-dose and 3-dose hepatitis B vaccine schedules in people with cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 November 2024